Integrative genomic and immune landscape analysis of intimal sarcomas for emerging therapeutic targets and immunotherapy strategies.

All five intimal sarcoma samples harbored MDM2 amplification confirming their diagnosis, along with co-amplification of CPM and SLC35E3.

• Whole transcriptome and whole exome sequencing were performed on 5 intimal sarcoma cases using FFPE tissue.
• MDM2 amplification was present in all samples, consistent with the known molecular hallmark of intimal sarcoma.
• Co-amplification of CPM (carboxypeptidase M) and SLC35E3 was identified across all cases.
• Copy number alteration detection was performed as part of the computational analyses.

All intimal sarcoma samples expressed PD-L1, suggesting potential sensitivity to immune checkpoint inhibitor therapy.

• PD-L1 expression was detected across all 5 cases analyzed.
• This finding was identified through computational analyses of whole transcriptome sequencing data.
• PD-L1 expression was discussed in the context of amenability to immunotherapy.

The immune cell composition of intimal sarcomas was characterized by a prevalence of CD4+ memory resting T-cells and M2 macrophages.

• Immune cell profiling was performed computationally on the 5 intimal sarcoma cases.
• CD4+ memory resting T-cells and M2 macrophages were the predominant immune cell types identified.
• Variable concentrations of naïve B-cells, CD8+ T-cells, and monocytes were also detected across samples.
• The immune infiltrate landscape was assessed as part of the integrative genomic and immune analysis.

Intimal sarcomas showed upregulation of immunoglobulins and immune response pathways including IL6/JAK/STAT3, TNF-α via NF-kB signaling, and interferon gamma response.

• Differential gene expression analysis was performed as part of the computational analyses.
• Upregulated pathways included IL6/JAK/STAT3 signaling, TNF-α via NF-kB signaling, and interferon gamma response.
• Immunoglobulin gene upregulation was also identified.
• These findings further suggested a potential sensitivity to immunotherapy in this tumor type.

The study identified potential therapeutic molecular targets in intimal sarcomas beyond MDM2 through variant calling and copy number alteration analyses.

• Whole exome sequencing with variant calling was used to identify somatic mutations across the 5 cases.
• The study aimed to detect potential targets apart from MDM2, given the rarity and poor chemotherapy sensitivity of intimal sarcomas.
• Intimal sarcomas arise mainly from the pulmonary artery and are characterized by late diagnosis and high mortality.
• The authors noted that further studies involving larger case series are required to validate these results.